

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 December 2021 (09.12.2021)




(10) International Publication Number
WO 2021/245619 A1

- (51) **International Patent Classification:**
C07K 16/28 (2006.01) *A61K 39/395* (2006.01)
A61P 11/06 (2006.01)
- (21) **International Application Number:**
PCT/IB2021/054921
- (22) **International Filing Date:**
04 June 2021 (04.06.2021)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/035,021 05 June 2020 (05.06.2020) US
62/706,245 06 August 2020 (06.08.2020) US
63/112,919 12 November 2020 (12.11.2020) US
- (71) **Applicant:** **ASTRAZENECA AB** [SE/SE]; SE-151 85 Södertälje (SE).
- (72) **Inventors:** **GARCIA GIL, Maria Esther**; AstraZeneca BioPharmaceutical Medical, Plaça de Gal·la Placidia, 1-3, Utopicus, 08006 Barcelona (ES). **ZANGRILLI, James**; c/o AstraZeneca Pharmaceuticals LP, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **BURDEN, Anne**; Ardnahor Consulting Ltd., Ardnahor, Barbour Road, Kilcreggan, Argyll & Bute G84 0JA (GB). **KREINDLER, James**; AstraZeneca Pharmaceuticals LP, One MedImmune Way, Gaithersburg, Maryland 20878 (US).

- (74) **Agent:** **ASTRAZENECA INTELLECTUAL PROPERTY**; Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) **Title:** METHODS FOR TREATING SEVERE ASTHMA IN PATIENTS WITH NASAL POLYPOSIS

FIGURE 1



(57) **Abstract:** Provided herein are methods of reducing exacerbations of asthma in an asthma patient with nasal polyposis, comprising administering to the patient an effective amount of the anti-interleukin-5 receptor (IL-5R) antibody benralizumab or an antigen-binding fragment thereof.

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*